SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical Industries reports 34% rise in Q4 consolidated net profit

23 May 2024 Evaluate

Sun Pharmaceutical Industries has reported results for fourth quarter (Q4) and year ended March 31, 2024.

The company has reported net profit of Rs 867.60 crore for the quarter under review as compared to net loss of Rs 1,020.82 crore for the same quarter in the previous year. However, total income of the company decreased by 5.12% at Rs 5,758.02 crore for Q4FY24 as compared Rs 6,068.52 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 33.77% rise in its net profit at Rs 2,654.58 crore for fourth quarter ended March 31, 2024 as compared to Rs 1,984.47 crore for the same quarter in the previous year. Total income of the company increased by 11.37% at Rs 12,588.84 crore for Q4FY24 as compared Rs 11,303.95 crore for the corresponding quarter previous year.

For the year ended March 31, 2024, the company has reported 69.05% rise in its net profit at Rs 2,858.18 crore as compared to Rs 1,690.72 crore for the previous year. However, total income of the company decreased by 1.66% at Rs 20,740.93 crore for year under review as compared to Rs 21091.17 crore for year ended March 31, 2023.

For the year ended March 31, 2024, on the consolidated basis, the company has reported 13.01% rise in its net profit at Rs 9,576.38 crore as compared to Rs 8,473.58 crore for the previous year. Total income of the company increased by 11.97% at Rs 49,851.04 crore for year under review as compared to Rs 44,520.20 crore for year ended March 31, 2023.

Sun Pharma Inds. Share Price

1873.70 26.40 (1.43%)
11-May-2026 14:21 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1873.70
Dr. Reddys Lab 1290.05
Cipla 1306.90
Zydus Lifesciences 954.35
Lupin 2277.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×